Texas-based Zeteo Biomedical has announced the launch of two new devices for intranasal delivery of dry powders: the CygnusMR multi-dose device and the CygnusSDX single dose disposable device. In 2022, the company announced the launch of its ZEOx1 OrionMRQ multi-dose nasal device for delivery of liquid drugs and vaccines. According to Zeteo, the new dry powder nasal devices can be configured for use with various animal species or for human use, including for pediatric patients.
Both of the new devices are based on Zeteo’s ZTech form fill and seal blister packaging system. According to the company’s web site, ZTech packaging includes micro-nozzles inside each blister that can be modified to achieve specific aerosolization characteristics.
Zeteo Biomedical CEO Timothy Sullivan commented, “The CygnusMR nasal delivery device is the industry’s first cartridge-reloadable nasal powder delivery system, featuring onboard storage for up to six unit doses and a replaceable nasal tip. Both the CygnusMR and CygnusSDX devices have undergone extensive analytical and in vivo preclinical testing over the past several years to ensure optimal performance and reliability.”
Read the Zeteo Biomedical press release
